Cassell A 3rd, Manobah B, Willie S. Diagnostic and therapeutic challenges of rare urogenital cancers: urothelial carcinoma of the renal pelvis, ureters and urethra. World J Oncol. 2021;12(1):20–7. https://doi.org/10.14740/wjon1360.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

Article  PubMed  Google Scholar 

Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–4. https://doi.org/10.1111/iju.13376.

Article  PubMed  Google Scholar 

Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79(1):62–79. https://doi.org/10.1016/j.eururo.2020.05.042.

Article  CAS  PubMed  Google Scholar 

Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016;70(3):458–66. https://doi.org/10.1016/j.eururo.2015.06.042.

Article  CAS  PubMed  Google Scholar 

van Doeveren T, van de Werken HJG, van Riet J, Aben KKH, van Leeuwen PJ, Zwarthoff EC, et al. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review Urol Oncol. 2020;38(6):590–8. https://doi.org/10.1016/j.urolonc.2020.01.008.

Article  CAS  PubMed  Google Scholar 

Cathomas R, Lorch A, Bruins HM, Comperat EM, Cowan NC, Efstathiou JA, et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81(1):95–103. https://doi.org/10.1016/j.eururo.2021.09.026.

Article  PubMed  Google Scholar 

Chester JD. Unifying themes in urothelial cancers. Eur Urol. 2021;79(1):80–1. https://doi.org/10.1016/j.eururo.2020.09.045.

Article  PubMed  Google Scholar 

Meireles S, Dias N, Martins D, Dias C, Gonçalves M, Silva J, et al. Prognostic value of bladder involvement in the outcome of upper tract urothelial carcinoma. Diagnostics (Basel). 2023;13(1):153. https://doi.org/10.3390/diagnostics13010153.

Article  PubMed  Google Scholar 

Aragon-Ching JB, Werntz RP, Zietman AL, Steinberg GD. Multidisciplinary management of muscle-invasive bladder cancer: current challenges and future directions. Am Soc Clin Oncol Educ Book. 2018;38:307–18. https://doi.org/10.1200/EDBK_201227.

Article  PubMed  Google Scholar 

Dobruch J, Oszczudlowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas). 2021;57(8):749. https://doi.org/10.3390/medicina57080749.

Article  PubMed  PubMed Central  Google Scholar 

Ghandour R, Singla N, Lotan Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer. Trends Cancer. 2019;5(7):426–39. https://doi.org/10.1016/j.trecan.2019.05.011.

Article  CAS  PubMed  Google Scholar 

Stecca C, Abdeljalil O, Sridhar SS. Metastatic urothelial cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol. 2021;13:17588359211047352. https://doi.org/10.1177/17588359211047352.

Article  CAS  PubMed Central  Google Scholar 

National Cancer Institute (NCI), National Institutes of Health (NIH). Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: bladder cancer; 2002. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 14 April 2023.

Flaig TW, Spiess PE. NCCN clinical practice guidelines in oncology: bladder cancer Version 3.2023; 2023. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 19 July 2023.

Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016;14(1):1–20. https://doi.org/10.1016/j.ejcsup.2016.01.001.

Article  PubMed  PubMed Central  Google Scholar 

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–4. https://doi.org/10.1016/s1470-2045(10)70275-8.

Article  PubMed  Google Scholar 

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8. https://doi.org/10.1200/jco.2011.34.8433.

Article  PubMed  Google Scholar 

Russell BM, Boussi L, Bellmunt J. Management of advanced urothelial carcinoma in older and frail patients: have novel treatment approaches improved their care? Drugs Aging. 2022;39(4):271–84. https://doi.org/10.1007/s40266-022-00933-2.

Article  CAS  PubMed  Google Scholar 

Gupta S, Bellmunt J, Plimack ER, Sonpavde GP, Grivas P, Apolo AB, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC) [ASCO abstract]. J Clin Oncol. 2022;40(16_Suppl):4577. https://doi.org/10.1200/JCO.2022.40.16_suppl.4577.

Article  Google Scholar 

Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. ScientificWorldJournal. 2018;2018:5682078. https://doi.org/10.1155/2018/5682078.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9. https://doi.org/10.1200/JCO.2011.37.3571.

Article  CAS  PubMed  Google Scholar 

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–41. https://doi.org/10.1016/j.eururo.2006.12.029.

Article  CAS  PubMed  Google Scholar 

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. https://doi.org/10.1200/JCO.2000.18.17.3068.

Article  PubMed  Google Scholar 

von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. https://doi.org/10.1200/JCO.2005.07.757.

Article  CAS  PubMed  Google Scholar 

Franza A, Pirovano M, Giannatempo P, Cosmai L. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations. Future Oncol. 2022;18(19):2455–64. https://doi.org/10.2217/fon-2021-1151.

Article  CAS  PubMed  Google Scholar 

D’Angelo A, Chapman R, Sirico M, Sobhani N, Catalano M, Mini E, et al. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemother Pharmacol. 2022;90(3):191–205. https://doi.org/10.1007/s00280-022-04459-7.

Article  PubMed  PubMed Central  Google Scholar 

Katims AB, Reisz PA, Nogueira L, Truong H, Lenis AT, Pietzak EJ, et al. Targeted therapies in advanced and metastatic urothelial carcinoma. Cancers (Basel). 2022;14(21):5431. https://doi.org/10.3390/cancers14215431.

Article  CAS  PubMed  Google Scholar 

Maas M, Stuhler V, Walz S, Stenzl A, Bedke J. Enfortumab vedotin - next game-changer in urothelial cancer. Expert Opin Biol Ther. 2021;21(7):801–9. https://doi.org/10.1080/14712598.2021.1865910.

Article  CAS  PubMed  Google Scholar 

Mantia CM, Sonpavde G. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(5):449–55. https://doi.org/10.1080/14737140.2022.2069563.

Article  CAS  PubMed  Google Scholar 

Mathew Thomas V, Tripathi N, Agarwal N, Swami U. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(4):335–41. https://doi.org/10.1080/14737140.2022.2049763.

Article  CAS  PubMed  Google Scholar 

Muilwijk T, Akand M, Van der AAF, Dumez H, De Meerleer G, Van Raemdonck D, et al. Metastasectomy of oligometastatic urothelial cancer a single-center experience. Transl Androl Urol. 2020;9(3):1296–305. https://doi.org/10.21037/tau-19-624.

Article  PubMed  PubMed Central  Google Scholar 

Ogihara K, Kikuchi E, Watanabe K, Kufukihara R, Yanai Y, Takamatsu K, et al. Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy? Oncotarget. 2017;8(67):111819–35. https://doi.org/10.18632/oncotarget.22911.

Article  PubMed  PubMed Central  Google Scholar 

Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81. https://doi.org/10.1200/jco.1999.17.10.3173.

Article  CAS  Google Scholar 

Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, et al. The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol. 2018;73(4):543–57. https://doi.org/10.1016/j.eururo.2017.09.030.